logo
Plus   Neg
Share
Email

Alexion To Acquire Syntimmune - Quick Facts

Alexion Pharmaceuticals, Inc. (ALXN) and Syntimmune announced a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor. Alexion will acquire Syntimmune for an upfront payment of $400 million, with the potential for additional milestone-dependent payments of up to $800 million, for a total value of up to $1.2 billion.

Syntimmune's lead candidate, SYNT001, is a monoclonal antibody that specifically blocks FcRn-IgG interactions and is being studied in multiple Phase 1b/2a trials for the treatment of IgG-mediated autoimmune diseases.

"Targeting FcRn holds great promise in transforming the treatment of IgG-mediated diseases. SYNT001 has successfully demonstrated proof of mechanism - the ability to rapidly lower IgG levels - in early clinical studies and has the potential to treat a number of rare IgG-mediated diseases," said Ludwig Hantson, CEO of Alexion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google Stadia, the tech giant's game streaming service that was unveiled in June, has announced it will launch 12 games on November 19. To celebrate the start of holiday season, coffee retail giant Starbucks Corp. (SBUX) is offering a Happy Hour deal on Thursday, November 14. On November 14 from 2-7 p.m., Starbucks customers can buy one, get one free on any handcrafted beverage, including holiday beverages, size grande or larger. Starbucks... Walmart said it has hired more than 243,000 military veterans nationwide since 2013 and remains ahead of schedule to meet its goal of hiring 250,000 military veterans by the end of 2020. The retail giant introduced the Veterans Welcome Home Commitment on Memorial Day 2013, as part of its commitment to service members and their families. The company's initial goal was to hire 100,000 veterans.
Follow RTT
>